Phase ii trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
暂无分享,去创建一个
Manal M. Hassan | R. Wolff | Lianchun Xiao | K. Elsayes | A. Kaseb | H. Al-Shamsi | J. Yao | A. Shalaby | M. Iwasaki | Lauren Girard | Sheree H. Cheung | Van Nguyen | R. Abdel-Wahab | H. Hassabo | J. Morris | Kanwal Singh | ahmed O Kaseb | Jeffrey s Morris | Michiko iwasaki | humaid O al-shamsi | Kanwal Pratap singh | raghav | lauren girard | sheree cheung | Van nguyen | Khaled M elsayes | lianchun Xiao | reham abdel-Wahab | ahmed s shalaby | Manal hassan | hesham M hassabo | robert a Wolff | James c Yao | raghav
[1] M. Kudo,et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[2] Joon-Oh Park,et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. , 2015 .
[3] M. Kudo,et al. EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. , 2014 .
[4] A. Kaseb. Beyond the Basics: The Differential Effects of Demographics and Hepatitis Status on Treatment Outcome in Hepatocellular Carcinoma , 2013, Oncology.
[5] Yoon-Koo Kang,et al. Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study , 2013, Oncology.
[6] I. Makhoul,et al. Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma , 2013, American journal of clinical oncology.
[7] C. Porta,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.
[8] P. Philip,et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer , 2012, Cancer.
[9] S. Fan,et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease , 2012, Investigational New Drugs.
[10] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[11] Jeffrey S. Morris,et al. Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial , 2012, Oncology.
[12] R. Finn,et al. Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.
[13] Jeffrey S. Morris,et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[15] T. Berg,et al. Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma , 2007, The American Journal of Gastroenterology.
[16] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[17] Y. Takeda,et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin‐2 and hypoxia‐induced factor‐1a , 2006, Liver international : official journal of the International Association for the Study of the Liver.
[18] E. Taniguchi,et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. , 2004, Journal of hepatology.
[19] H. Yu,et al. Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma? , 2003, Modern Pathology.
[20] M. Kuwano,et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. , 2002, Cancer research.
[21] M. Kojiro,et al. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. , 1999, International journal of oncology.
[22] M. Makuuchi,et al. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. , 1999, The Journal of clinical investigation.
[23] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[24] Zu-bing Chen,et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus , 2009, Medical oncology.
[25] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[26] N. Fausto. Growth factors in liver development, regeneration and carcinogenesis. , 1991, Progress in growth factor research.
[27] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.